Domainex announces the appointment of Dr. Eddy Littler as non-executive Chairman

CAMBRIDGE, UK - Jun 2, 2020 - Following the retirement of Tony Brampton, Eddy Littler has been appointed as non-executive Chairman of Domainex Ltd.

Eddy began his research career at the University of Leeds obtaining his PhD in virology. After postdoctoral research at McMaster University in Canada, he joined the Paterson Institute for Cancer Research in Manchester. Eddy held senior positions with Wellcome Research Laboratories, GSK and Medivir, where he led the team that discovered Olysio which was a major drug for treatment of hepatitis C virus. Eddy became CEO of Domainex in May 2008 and developed Domainex to become one of the UKs leading drug discovery CROs. In October 2016, Eddy joined ReViral as CEO. ReViral is a UK-based biotechnology company developing therapies for respiratory syncytial virus by developing novel first-in-class medicines and in 2018 Eddy led the fundraising of $55million Series B investment for the Company. He became COO in June 2019 as the Company moved into Phase 2 development. Eddy is also Chairman of Neuro-Bio based in Oxford, researching treatments for Alzheimers disease.

Domainexs retiring chairman Tony Brampton commented: I am delighted that Eddy Littler has agreed to return to Domainex as Chairman. I joined the Domainex board as a non-executive director in 2012 and had the privilege of working with Eddy for a number of years. His deep understanding of Domainexs business and extensive drug discovery expertise will be invaluable to the management team led by our CEO, Tom Mander, as we pursue an accelerated growth strategy and maintain our position at the forefront of drug discovery technology providers.

Eddy Littler said: I am pleased to have returned to Domainex. During my time as CEO I came to understand how much diverse drug discovery is driven by contract research organisations and how it is possible to establish a reputation for high-quality research within the sector. Since my departure, Domainex has moved from strength to strength growing in size and also in its establishment of advanced biological technologies for screening and developing compounds into drugs. I am eagerly anticipating taking over the position of Chairman and working with the Domainex team to help continue the successful years it has had under Tony Bramptons guidance.

Ends

For more information contact:

Domainex
Dr Tom Mander
E: tom.mander@domainex.co.uk

Media Relations - Sciad Communications
Deborah Cockerill / Victoria Deaner
T: +44(0)20 3405 7892
E: domainex@sciad.com

Notes to Editors

About Domainex

Domainex is a leading integrated medicines research service partner working with ambitious life science organisations from around the globe. We have been setting new standards in research since 2001, working collaboratively with pharmaceutical and biotechnology companies, patient foundations and leading academic institutions.

We provide innovative and customised biology and chemistry services to advance the disease research projects of our partners, from target expression to pre-clinical development candidate nomination. Working with Domainex maximises the chance of successful progression for our partners research and our approach consistently saves up to 30% of the time needed to discover new medicines by comparison with the industry average. Our innovative science and extensive technical capabilities enable us to produce novel medicines to treat diseases with strong commercial potential. We work closely and collaboratively with our sponsors to understand their aspirations, bringing our ideas, know-how and wealth of experience to bear on their projects.

Our highly qualified and experienced team of dedicated research scientists has an unrivalled breadth of knowledge, access to a wide range of technologies and a proven track record of successful innovation in solving research challenges including being named on over 60 patent applications and the invention of numerous candidate drugs. We aim to deliver successful outcomes efficiently and quickly, setting the highest possible benchmark in medicines research.

Full information about Domainex and our award-winning services can be found at www.domainex.co.uk.